|
|
|
ACUR - Acura Pharmaceuticals, Inc.
Acura
Pharmaceuticals, Inc. (ACUR) is a pharmaceutical company focused on
the development and commercialization of abuse-deterrent formulations
of opioid analgesics and other drugs. The company's products utilize
its proprietary Aversion and Impede technologies to deter abuse and
misuse.
Acura Pharmaceuticals' lead product is Oxaydo, an
immediate-release formulation of oxycodone that utilizes the company's
Aversion technology to deter abuse through the use of inactive
ingredients that make it difficult to crush, snort, or inject the
drug. The company also has a pipeline of abuse-deterrent products in
development, including hydrocodone, hydromorphone, and morphine
formulations.
The company has reported financial results for
the third quarter of 2021, reporting revenues of $1.2 million,
compared to $1.5 million in the same period in the previous year.
Acura Pharmaceuticals reported a net loss of $2.8 million for the
quarter, compared to a net loss of $2.7 million in the same period in
the previous year.
Acura Pharmaceuticals has been focused on
advancing its pipeline of abuse-deterrent products and entering into
partnerships and collaborations with other companies. In December
2021, the company announced that it had entered into a licensing
agreement with Nuvo Pharmaceuticals to commercialize its
immediate-release abuse-deterrent oxycodone product in Canada.
However, the company's financial performance and operations may be
impacted by various factors, including the outcome of clinical trials,
regulatory changes, and competition in the pharmaceutical industry. In
addition, the ongoing opioid epidemic and public concern about the
abuse and misuse of prescription drugs may affect the market for Acura
Pharmaceuticals' products.
Overall, Acura Pharmaceuticals, Inc.
is a pharmaceutical company focused on the development and
commercialization of abuse-deterrent formulations of opioid analgesics
and other drugs. The company has a pipeline of abuse-deterrent
products in development and has entered into partnerships and
collaborations to advance its research and development efforts.
However, the company's financial performance and operations are
subject to various risks and uncertainties associated with the
pharmaceutical industry and the public health concerns around the
misuse of prescrip
|
|
|
|
|
